Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 13/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | S100A9 | P06702 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31647249 | 0.83 | ALDH1A1 (0.52) | ALDH1A1LMNAGAAMAPTHTT | |
| SCHEMBL2172819 | 0.81 | ALDH1A1 (0.56) | ALDH1A1LMNAGAAMAPTHTT | |
| SCHEMBL7677072 | 0.81 | ALDH1A1 (0.65) | ALDH1A1LMNAGAAMAPTNPSR1 | |
| SCHEMBL31454281 | 0.80 | ALDH1A1 (0.72) | ALDH1A1LMNAGAAMAPTHTT | |
| SCHEMBL516599 | 0.79 | ALDH1A1 (0.57) | ALDH1A1LMNAGAAMAPTHTT | |
| SCHEMBL517787 | 0.79 | ALDH1A1 (0.57) | ALDH1A1LMNAGAAMAPTHTT | |
| SCHEMBL2172648 | 0.79 | ALDH1A1 (0.38) | ALDH1A1LMNAGAAMAPTHTT | |
| SCHEMBL21633471 | 0.79 | ALDH1A1 (0.38) | ALDH1A1LMNAGAAMAPTHTT | |
| SCHEMBL2650456 | 0.78 | ALDH1A1 (0.59) | ALDH1A1LMNAGAAMAPTHTT | |
| SCHEMBL22718045 | 0.77 | ALDH1A1 (0.58) | ALDH1A1LMNAGAAMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158039-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2023-05-25 | — | — | US | disclosed |
| US-20210236508-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2021-08-05 | — | — | US | disclosed |
| CN-106986872-B | Bromodomain inhibitors | 艾伯维公司 | 2020-04-21 | — | — | CN | disclosed |
| US-20180296566-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2018-10-18 | — | — | US | disclosed |
| US-9994581-B2 | Bromodomain inhibitors | ABBVIE INC. (US) | 2018-06-12 | — | — | US | disclosed |
| EP-2797918-B1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2017-11-29 | — | — | EP | disclosed |
| US-20170015673-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. | 2017-01-19 | — | — | US | disclosed |
| US-20160237084-A1 | DIHYDRO-PYRROLOPYRIDINONE INHIBITORS | ABBVIE INC (US) | 2016-08-18 | — | — | US | disclosed |
| US-20160143916-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2016-05-26 | — | — | US | disclosed |
| US-9321764-B2 | Dihydro-pyrrolopyridinone inhibitors | ABBVIE INC. (US) | 2016-04-26 | — | — | US | disclosed |
| WO-2013097601-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2013-07-04 | — | — | WO | disclosed |
| EP-2346819-B1 | NAPHTHYLACETIC ACIDS | HOFFMANN LA ROCHE (CH) | 2013-04-10 | — | — | EP | disclosed |
| EP-2346819-B1 | NAPHTHYLACETIC ACIDS | HOFFMANN LA ROCHE (CH) | 2013-04-10 | — | — | EP | disclosed |
| CN-102216265-A | Naphthylacetic acid | HOFFMANN LA ROCHE | 2011-10-12 | — | — | CN | disclosed |
| EP-2346819-A1 | NAPHTHYLACETIC ACIDS | F. Hoffmann-La Roche AG (CH) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010055004-A1 | NAPHTHYLACETIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010055004-A1 | NAPHTHYLACETIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-20 | — | — | WO | disclosed |
| US-20100125058-A1 | NAPHTHYLACETIC ACIDS | CHEN LI | 2010-05-20 | — | — | US | disclosed |
| US-20100125058-A1 | NAPHTHYLACETIC ACIDS | CHEN LI | 2010-05-20 | — | — | US | disclosed |
| US-20100125058-A1 | NAPHTHYLACETIC ACIDS | CHEN LI | 2010-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180296566-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | ALDH1A1 1794/4885LMNA 1293/4885GAA 1927/4885 |
| US-20100125058-A1 | NAPHTHYLACETIC ACIDS | HRH2, HRH1, HRH3 | ALDH1A1 746/4885LMNA 1698/4885GAA 671/4885 |
| US-20160237084-A1 | DIHYDRO-PYRROLOPYRIDINONE INHIBITORS | DPYD, QDPR, DHFR | ALDH1A1 439/4885LMNA 4054/4885GAA 2854/4885 |
| US-20170015673-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD8 | ALDH1A1 2033/4885LMNA 1065/4885GAA 1443/4885 |
| US-20230158039-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | ALDH1A1 1794/4885LMNA 1293/4885GAA 1927/4885 |
| US-20160143916-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | ALDH1A1 1794/4885LMNA 1293/4885GAA 1927/4885 |
| US-20210236508-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | ALDH1A1 1794/4885LMNA 1293/4885GAA 1927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.